Connect with us

Technology

Withings Introduces StethO Sense, Bringing Heart and Lung Sound Analysis to BeamO

Published

on

StethO Sense, a new Withings+ service powered by eMurmur® and StethoMe, brings on-demand AI-powered heart sound analysis and breathing pattern insights to BeamO users, allowing families to track changes in heart sounds and breathing patterns early from home.

ISSY-LES-MOULINEAUX, France, Sept. 4, 2026 /PRNewswire/ — Withings today announced StethO Sense, a new service within Withings+, the premium membership tier of the Withings app, that gives parents a closer listen to what their child’s bodies are already saying. It brings on-demand AI-powered analysis of heart and lung recordings to BeamO, the company’s compact, FDA-cleared health device that combines a clinical-grade thermometer, 1-lead ECG, and digital stethoscope in one tool.

Powered by eMurmur Heart AI for abnormal murmur detection, and StethoMe for breathing sound insights, StethO Sense provides BeamO users with the ability to analyze heart and lung recordings from the comfort of the home. Withings+ members can access unlimited analyses at home, with results available in seconds. StethO Sense results are not a diagnosis and are intended to be shared with a healthcare professional.1

“Hearts don’t always tell us when something is wrong. A heart murmur, an unusual sound caused by blood flowing through the heart, can go unnoticed for years. StethO Sense lets families record heart sounds at home, in seconds, as often as they want, and build a record they can bring to their doctor. It doesn’t replace a visit; rather, StethO Sense gives you additional health data to bring to one,” said Livia Robic, Product Manager, BeamO.

How StethO Sense Works
From the StethO Sense section of the Withings+ app, users can select a heart or lung recording and instantly start the analysis. Heart recordings are taken at one of four standard positions, while lung recordings are taken at up to eight positions at 12 years of age and above, and six positions for those below 12 years of age. BeamO guides users through the process with an anatomical diagram. Results are delivered within seconds in the Withings app.1,1b

StethO Sense complements the Withings+ Cardio Check-Up service, which provides a cardiologist review of a user’s ECG within 24 hours, up to four times a year. The two services are complementary: Cardio Check-Up provides a cardiologist’s review of an ECG, while StethO Sense provides unlimited AI-assisted analysis of heart and lung recordings that users can share with a healthcare professional.1

Designed for Families and Everyday Health Monitoring
StethO Sense is designed to provide peace of mind to people who want additional insight into the health signals they can capture at home, including:

For children & families:

Identify changes in breathing sounds: StethoMe’s Breathing Index gives a score, 0–100, based on their breathing sounds, breathing quality, breathing rate, plus respiratory rhythm, and heart rate, helping families notice changes over time. It is designed to give insight into day-to-day breathing patterns and if necessary to be shared directly with a healthcare professional, with a report exportable from the Withings+ app.Track heart murmurs: StethO Sense lets parents record their child’s heart sounds at home, tracking heart murmurs and changes in heart sounds. It is designed to be shared directly with a healthcare professional and a report is exportable from the Withings+ app.Spot early symptoms before an urgent care visit: StethO Sense also tracks changes in heart which is particularly important during winter months.

Adults monitoring their heart health:

Track heart murmurs: Heart murmurs are relatively common, affecting nearly one in four adults.6 While many are harmless, murmurs can sometimes be an early sign of valvular heart disease, a condition that often develops silently and is easy to miss without a regular check. A 2024 study of over 4,200 older adults found that more than a quarter had valvular heart disease that had never been diagnosed.7 StethO Sense gives users a way to record and track heart sounds over time, rather than only at an annual check-up, and to share those recordings with a healthcare professional.Athletes: StethO Sense is valuable for athletes as heart murmur checks are increasingly part of routine sports physicals, particularly in the US, where screening for conditions like hypertrophic cardiomyopathy (HCM),8 a leading cause of sudden cardiac events in young athletes, is a growing focus.

eMurmur: Heart Sound Analysis
StethO Sense’s heart sounds analysis is provided by eMurmur2, a medical AI company that built an open intelligence layer to power auscultation hardware and software. eMurmur Heart AI analyzes BeamO heart sound recordings in seconds, and distinguishes between the absence of a murmur, innocent murmurs and abnormal murmurs. Across multiple blinded prospective clinical studies, eMurmur Heart AI demonstrated approximately 90% sensitivity and specificity for pathologic murmur detection.3 It also provides the heart rate and a confidence score for its findings. eMurmur Heart AI is FDA-cleared for use on both children and adults.4

StethoMe: Breathing Sound Insights
StethO Sense also brings a new Breathing Index from StethoMe,5a an AI company specializing in pulmonary sound analysis. The Breathing Index provides a score 0–100 based on breathing sounds and quality of breathing. It is designed to help people notice changes in their breathing patterns over time, with a guided protocol that adapts to age (six recording points for children, eight for adults). In the US, StethoMe’s Breathing Index is offered as a general wellness feature.5b

Extending StethO Sense to Healthcare Professionals
StethO Sense also extends to BeamO PrO, the professional version of the device used by clinicians and care teams. With eMurmur’s FDA-cleared Heart AI, healthcare professionals can perform heart sound assessments efficiently across a range of care settings, including nursing homes. AI-assisted auscultation has also been shown to reduce inappropriate cardiology referrals by up to 50–75%,3 helping care teams prioritize the patients who need further investigation. The technology is designed to support clinical workflows by providing additional information that can be considered alongside a healthcare professional’s assessment.

Availability
StethO Sense will be available beginning October 1, 2026, exclusively for Withings+ users. To celebrate the launch, existing BeamO users who purchased their device before October 1, 2026 will receive a complimentary one-month trial of Withings+. Consumers purchasing BeamO for $249.95 starting October 1, 2026 will get a 1-month free trial of Withings+ to experience StethO Sense.

Learn more about StethO Sense and BeamO at withings.com/beam-o or visit the Withings booth at IFA: Beauty Hub, Booth H13-107, from September 4–8, 2026, in Berlin, Germany.

Notes to Editors

About BeamO
BeamO is Withings’ health thermometer, combining a clinical-grade thermometer, 1-lead electrocardiogram, and digital stethoscope in a single compact FDA-cleared device. Designed for the whole family, BeamO lets anyone check their temperature, and heart and lung sounds in a minute, then seamlessly share the results with a doctor. BeamO is intended to complement, not replace, an in-person medical exam. Learn more at withings.com.

About Withings+
Every BeamO comes with a complimentary one-month trial of Withings+,9 automatically activated at setup. Withings+ unlocks the complete suite of advanced health scores and personalized AI-driven feedback for $9.95 / €9.95 / £8.95 per month, or $99.50 / €99.50 / £89.50 per year.

Advanced Health Services: get unlimited, on-demand StethO Sense analysis for heart murmurs and breathing pattern insights, plus a cardiologist-reviewed ECG via the Cardio Check-Up service

AI Health Assistant: an on-demand coach that answers health questions, helps you interpret latest results, and recommends actionable next steps

Withings Intelligence: proactively analyzes how data evolves over time, flags negative trends, and shows how overall habits and changes shape long-term health

Lifetime Guarantee: device protection for as long as you use it, reflecting Withings’ commitment to long-term health partnership

About the Partners Powering StethO Sense
eMurmur: a medical AI company offering an open intelligence layer to power auscultation hardware and software. eMurmur also offers a separate lung sound AI, which is not part of the StethO Sense integration.

StethoMe: an AI company specializing in pulmonary sound analysis. In the United States, the StethoMe Breathing Index is offered as a general wellness feature and is not FDA-cleared.

About Withings
A pioneer in real-life health monitoring, Withings created the first connected scale in 2009 and has continually innovated since then to offer an ecosystem of clinically validated connected devices, used by 12 million people worldwide, as well as by numerous renowned healthcare centers and research institutes. Withings collaborates with leading research institutions including Stanford and Harvard. Its ecosystem spans hybrid smartwatches and blood pressure monitors that help people track their health and act early. Available at withings.com.

Media Contact
Alex McKechnie
alex.mckechnie@12080group.com
475.399.4056

References & Disclaimers

1AI results are diagnosis-assisting only. Final clinical assessment must be performed by a qualified healthcare provider.

1bStethO Sense is a service that combines BeamO recordings with third-party analysis software.

2eMurmur is a trademark of CSD Labs GmbH, a healthcare technology company specializing in AI-powered digital auscultation and cardiac sound analysis. eMurmur Heart AI is developed and maintained by CSD Labs and is integrated into StethO Sense for heart sound analysis only. Its algorithm has been validated in peer-reviewed clinical studies across pediatric and adult populations. For more information, visit www.emurmur.com.

3Thompson WR et al. Pediatric Cardiology. 2019;40(3):623–629. doi:10.1007/s00246-018-2036-z. Study of 603 patients; sensitivity 93% (CI 90–95%), specificity 81% (CI 75–85%). FDA 510(k): K181988 (eMurmur ID, 2019); K220766 (eMurmur Heart AI, 2022).

4In the United States, eMurmur’s algorithm is FDA-cleared for use on both adults and children. eMurmur results are diagnosis-assisting only for healthcare professional use. Final clinical assessment must be performed by a qualified healthcare provider.

5aStethoMe is a general wellness product in the US. It is not FDA-cleared and is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider with any health concerns. Its AI algorithms analyze respiratory sound patterns and are the result of 8+ years of research with academic partners including Poznan University of Medical Sciences. For more information, visit www.stethome.com.

5bStethoMe’s Breathing Index is a wellness feature intended for general respiratory sound tracking. It is not intended for use by individuals with diagnosed respiratory conditions (including but not limited to asthma, COPD, bronchitis, bronchiolitis, etc…) or as a substitute for medical advice, diagnosis, or treatment.

6Heggdal M, et al. Heart murmurs in the general population: diagnostic value and prevalence from the Tromsø Study. 2025.

7Tsampasian V, Militaru C, Pareek N, et al. Prevalence of asymptomatic valvular heart disease in the elderly population: a community-based echocardiographic study. European Heart Journal – Cardiovascular Imaging, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11288748/

8American Heart Association. “HCM in Young Adults and Student Athletes.” Accessed August 26, 2026. https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/hcm-in-young-adults-and-student-athletes

9Subject to Withings terms and conditions, available at: https://www.withings.com/us/en/legal/services-terms-and-conditions

View original content to download multimedia:https://www.prnewswire.com/news-releases/withings-introduces-stetho-sense-bringing-heart-and-lung-sound-analysis-to-beamo-302869284.html

SOURCE Withings

Continue Reading

Technology

TECNO Wins Two IFA Global Product Technology Innovation Awards for Modular Phone and Tonino Lamborghini TECNO TAURUS

Published

on

By

BERLIN, Sept. 5, 2026 /PRNewswire/ — TECNO, a global AI-driven innovative technology brand, achieved two IFA Global Product Technology Innovation Awards at IFA 2026:

Tonino Lamborghini TECNO TAURUS took the Miniaturized Gaming PC Technology Innovation Gold Award, standing out with its Italian aesthetics and exceptional performance in the compact body. The TECNO Modular Phone was honored with the Ultra-Slim Magnetic Modular Technology Innovation Gold Award, praised for its ultra-slim craftsmanship and unique modular magnetic technology.

These awards once again demonstrate TECNO’s sustained breakthroughs in product innovation and industry-leading craftsmanship in design excellence. The Global Product Technology Innovation Awards were established in 2014 by IDG, IFA, and DIHK to celebrate excellence across the global consumer electronics industry. The awards honor products that set new industry benchmarks and drive innovation through intelligent technology and user-centric design.

TECNO Modular Phone: The World’s Thinnest Modular Smartphone

At just 4.9mm, the TECNO Modular Phone is powered by proprietary Modular Magnetic Interconnection Technology. It combines a precision magnetic array with pogo-pin connectors, offering a flexible ecosystem for different needs. The host retains a 3000–4000mAh battery, while modules draw power directly for a snap-and-go experience. It also resolves the inherent conflict between rising AI computing demands and limited device space.

The technology has earned over 20 accolades from leading media, with CNET and Yanko Design naming it the Best of MWC 2026, and The Verge recognizing it as the Best Mobile Tech at MWC 2026.

Tonino Lamborghini TECNO TAURUS: One of the World’s Smallest Water-Cooling Gaming Mini-PCs

At around 6.36 liters, the panoramic transparent chassis of the Tonino Lamborghini TECNO TAURUS fuses iconic Italian design with raw engineering. Powered by the Intel® Core™ i9-13900HK and NVIDIA® GeForce RTX™ 5060 (614 AI TOPS, 145W TGP, DLSS 4), it achieves the pinnacle of performance, providing a high-fidelity gaming experience and high-efficiency AI workstation. The water-cooling system sustains peak frequencies, while 15 ports and WiFi 6E deliver connectivity. It was recognized with Yanko Design’s Best of MWC award.

In addition, TECNO made waves at IFA with the Next-Gen Bezelless Concept Phone featuring a revolutionary 0mm screen bezel, and the convertible laptop MEGABOOK T15 360 Pro. Relentlessly pushing the boundaries of design, performance, and AI innovation, TECNO is pioneering limitless possibilities for futuristic technology.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tecno-wins-two-ifa-global-product-technology-innovation-awards-for-modular-phone-and-tonino-lamborghini-tecno-taurus-302870739.html

Continue Reading

Technology

Morpho UV Printer Unveiled at IFA with Hands-On Live Creation

Published

on

By

BERLIN, Sept. 5, 2026 /PRNewswire/ — Morpho, a company specializing in UV printing technology, is showcasing its first desktop UV printer at IFA 2026, Hall 17-196. Visitors are observing Morpho’s colorful, textured prints, and some have the opportunity to print on a range of blank materials provided.

Morpho’s desktop UV printer can print on a wide range of materials, including wood, glass, leather, metal, and more, delivering vivid colors and tactile textures for customized results. At IFA 2026, the booth attracted interest from creators, educators, and technology professionals, who gathered to watch live demonstrations.

Among those who have tried Morpho’s printer, three aspects are most frequently highlighted: print quality, the moving gantry design, and overall ease of use.

Visitors are first drawn to the prints, which feature precise color reproduction and finely detailed textile textures. With G7 Master ColorSpace certification, Morpho ensures consistent tones across different pieces. The same level of precision is evident in the raised textures created by the industrial-grade printhead, which builds fine layers of ink for detailed, tactile surfaces. The printhead maintains fast carriage motion speeds of up to 600mm/s while preserving precise detail.

Attendees have also noted the printer’s compact desktop footprint. With its moving gantry architecture—where the entire gantry moves along both axes—the printer offers a large, fully enclosed print chamber that accommodates various objects while remaining desktop-friendly.

First-time users have given positive feedback on Morpho’s usability. The integrated Stereo Vision Smart Alignment™ System quickly captures an object’s height and contours, while Morpho Studio’s guided workflows help users move from idea to print with minimal setup.

Morpho’s team shared that the program has been in development for several years, with the goal of making UV printers a practical tool for everyday creative use. Founder Mingyu “Brett” Wang, formerly Global VP of R&D at DJI, commented, “We communicate directly with our community, listen to feedback, and make fast improvements.”

Ahead of IFA, Morpho’s Kickstarter campaign surpassed $10 million in support from over 2,800 backers worldwide. The company is committed to further developing its proprietary core technology and delivering reliable engineering for creators, makers, and small businesses.

Visit Morpho’s website to learn more.

About Morpho: Morpho develops desktop UV printers that bring industrial-grade printing and coloring to everyday materials, enabling creators to turn almost any physical surface into a canvas for their ideas.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/morpho-uv-printer-unveiled-at-ifa-with-hands-on-live-creation-302870741.html

Continue Reading

Technology

Society of Robotic Surgery and Puma Venture Capital Announce Winners of SRS Shark Tank 2026

Published

on

By

Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery’s annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.

HOLLYWOOD, Fla., Sept. 5, 2026 /PRNewswire-PRWeb/ — Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery’s annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.

SRS Shark Tank 2026 featured presentations from nine innovative companies. Each had five minutes to pitch their technology and five minutes to engage in a Q&A session with a panel of esteemed judges, including top surgeons, investors, and medical device experts. Companies were evaluated on innovation, impact on healthcare, market potential, business model, and presentation.

Drive Medical earned the top honor for the Pollywog System, the first easy-to-use robotic endoscope integrated with artificial intelligence. The platform is designed to give physicians faster, safer access to the small bowel, allowing diagnosis and treatment to be completed in a single session rather than across multiple procedures.

DeepQure secured second place with HyperQure, the world’s first extravascular renal denervation system for resistant hypertension. Delivered laparoscopically, the device wraps the renal artery from the outside to achieve complete denervation while avoiding the vessel lining.

Microsure came in third with MUSA-3, a microsurgical robot that downscales and stabilizes a surgeon’s hand movements during open super-microsurgical procedures, including free flap, lymphatic, and peripheral nerve surgery. The system received CE mark approval earlier this year.

The strength of the 2026 field extended well beyond the podium: every one of the nine presenting companies was placed in the top three by at least one judge. Reveal Surgical presented optical imaging technology that characterizes tissue for tumor assessment during surgery, and Symphera demonstrated a laparoscopic system that lets surgeons switch instrument tips at the push of a button. Tioga Cardiovascular showed its transcatheter approach to mitral and tricuspid valve replacement.

CardioSentry presented an AI platform for autonomous cardiac ultrasound, and Nina Medical showcased a completely non-invasive treatment for benign prostatic hyperplasia. LITLab rounded out the slate with mobile, high-fidelity surgical training labs that travel to health systems and medtech companies to train clinical teams onsite. Together the group reflected an unusually broad and competitive slate, spanning robotics, imaging, structural heart, urology, and surgical education.

The 2026 judging panel included Steve Bell, Rob Morgan, Dr. Santiago Horgan, Dr. Erik B. Wilson, Scott Zinober, and Babak Tehranchi, and the event was co-chaired by Amit Hazan and Dr. Vipul Patel.

Participating companies included:

Microsure, Symphera, LITLab, Reveal Surgical, DeepQure, Drive Medical, Nina Medical, CardioSentry, and Tioga Cardiovascular.

About the Society of Robotic Surgery:

Founded in 2012, the Society of Robotic Surgery (SRS) is guided by the fundamental principles of education and collaboration as a means to tackle the complex issues of robotic surgery. The SRS’ membership includes more than 20,000 physicians of all disciplines from around the world whose mission is to share information related to multi-centric studies, database collection, fellowship training and funding support related to robotic surgery. The SRS is the only multi-specialty robotic surgery society in the world with an annual meeting that includes updates in more than a dozen medical sub-specialties along with state-of-the-art plenary sessions and hot topic courses.

About Puma Venture Capital:

Puma Venture Capital is an investment firm seeking to leverage its surgeon venture partners to invest in all aspects of physical intelligence across every medical procedure — to improve patient outcomes, lift labor productivity, and lower system costs.

Media Contact

Ryan Julison, Society of Robotic Surgery, 1 3213776877, ryanjulison@gmail.com

View original content:https://www.prweb.com/releases/society-of-robotic-surgery-and-puma-venture-capital-announce-winners-of-srs-shark-tank-2026-302869733.html

SOURCE Society of Robotic Surgery

Continue Reading

Trending